MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.
By R. Collins, J. Armitage, S. Parish, P. Sleigh, R. Peto. The Lancet, 2003
2,873 citations recorded by the source corpus.
Subfields: Endocrinology, Diabetes and Metabolism, Surgery
View Paper: https://www.semanticscholar.org/paper/ad50ed2cfdceacebfedbf9e0a0ad00ba26baf91e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
- I. Graham
- Massimo F. Piepoli
- T. Ivanova
- L. Rydén
- F. Cosentino
- Joshua A. Beckman
- F. Paneni
- Alberico L. Catapano
In Surgery
- I. Graham
- Massimo F. Piepoli
- T. Ivanova
- F. Cosentino
- Joshua A. Beckman
- Alberico L. Catapano
- M. Creager
Citations in the corpus
- 2016 European Guidelines on cardiovascular disease prevention in clinical practice. (2016, background): “Statins, by decreasing LDL-C, reduce CV morbidity and mortality as well as the need for coronary artery interventions.(371,372) Statins at doses that effectively reduce LDL-C by at least 50% also seem to halt progression or even contribute to regression of coronary atherosclerosis.”
- European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) (2012, positive): “The Heart Protection Study (HPS) demonstrated that treatment with simvastatin 40mg reduced the risk of CHD and stroke in diabetic and non-diabetic individuals without prior myocardial infarction or angina pectoris.(436) The reactive treatment effect was independent of baseline cholesterol, although ”
- 2016 European Guidelines on cardiovascular disease prevention in clinical practice (2016, background): “Statins, by decreasing LDL-C, reduce CV morbidity and mortality as well as the need for coronary artery interventions.(371,372) Statins at doses that effectively reduce LDL-C by at least 50% also seem to halt progression or even contribute to regression of coronary atherosclerosis.”
- 2016 European Guidelines on cardiovascular disease prevention in clinical practice (2017, positive): “The Heart Protection Study (HPS) demonstrated that treatment with simvastatin 40 mg reduced the risk of CAD and stroke in people with DM and individuals without DM who had no prior AMI or angina pectoris [372].”